drugset / Trial / NCT00291967

Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants

NCT00291967

Phase 2 Completed 525 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelPrevention

Summary

To compare three formulations of Hib-MenAC vaccines mixed with Tritanrix™-HepB vaccine with that of Tritanrix™-HepB vaccine concomitantly administered with GSK Biologicals' Hiberix™ vaccine and Tritanrix™-HepB vaccine mixed with Hiberix™ vaccine and concomitantly administered with Wyeth Lederle's meningococcal C conjugate vaccine (Meningitec™), with respect to antibody response to vaccine antigens (meningococcal serogroups A and C and PRP) after a three-dose primary vaccination course.

Timeline

Start
2002-11
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Hib-MenAC conjugate vaccine Unknown
Subject Tritanrix-HepB Vaccine